Dexcom (DXCM) Other financing activities (2018 - 2026)

Dexcom (DXCM) has reported Other financing activities for 9 consecutive years, with -$1.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other financing activities fell 11.76% year-over-year to -$1.9 million in Q2 2026; TTM through Jun 2026 was -$7.4 million, a 17.46% decrease from a year earlier, with the FY2025 full-year figure at -$7.0 million, up 46.15% from the prior year.
• Other financing activities was -$1.9 million for Q2 2026 at Dexcom, roughly flat from -$1.9 million in the prior quarter.
• Over five years, Other financing activities peaked at $4.9 million in Q4 2023 and troughed at -$8.7 million in Q1 2024.
• A 5-year average of -$2.2 million and a median of -$1.7 million in 2025 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities sank 975.0% in 2022 and soared 590.0% in 2023, its largest moves.
• Over 5 years, Other financing activities stood at -$1.0 million in 2022, then soared by 590.0% to $4.9 million in 2023, then tumbled by 132.65% to -$1.6 million in 2024, then dropped by 18.75% to -$1.9 million in 2025, then changed by 0.0% to -$1.9 million in 2026.
• The last three Other financing activities figures came in at -$1.9 million (Q2 2026), -$1.9 million (Q1 2026), and -$1.9 million (Q4 2025), per Business Quant data.